Patents Assigned to Prothena Biosciences Limited
  • Methods of treating AL amyloidosis
    Patent number: 12240894
    Abstract: Antibody formulations and methods useful for treatment of patients with AL amyloidosis.
    Type: Grant
    Filed: May 8, 2023
    Date of Patent: March 4, 2025
    Assignee: Prothena Biosciences Limited
    Inventors: Gene Kinney, Wagner Marcelo Zago, Carol Karp, Radhika Tripuraneni
  • Tau immunotherapy
    Patent number: 12195525
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: January 14, 2025
    Assignee: Prothena Biosciences Limited
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20240309078
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: March 11, 2024
    Publication date: September 19, 2024
    Applicant: Prothena Biosciences Limited
    Inventors: Robin BARBOUR, Svetlana ALEXANDER, Mark E. RENZ, Shuning GAI, Tarlochan S. NIJJAR, Philip James DOLAN, III, Philip PAYNE
  • Treatment of Parkinson's disease
    Patent number: 12084491
    Abstract: The invention provides a method of treating, preventing or ameliorating Parkinson's disease with Prasinezumab.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: September 10, 2024
    Assignees: Prothena Biosciences Limited, F. Hoffmann-La Roche, Inc.
    Inventors: Gennaro Pagano, Wagner Zago
  • Antibodies recognizing sortilin
    Patent number: 12049497
    Abstract: The invention provides antibodies that specifically bind sortilin. The antibodies inhibit or delay pathologies associated with changes in progranulin levels and associated symptomatic deterioration.
    Type: Grant
    Filed: October 26, 2023
    Date of Patent: July 30, 2024
    Assignee: Prothena Biosciences Limited
    Inventors: Andriani Ioannou, Tarlochan S. Nijjar, Philip James Dolan, III, Wagner Zago
  • Humanized antibodies recognizing sortilin
    Patent number: 12049498
    Abstract: The invention provides antibodies that specifically bind sortilin. The antibodies inhibit or delay pathologies associated with changes in progranulin levels and associated symptomatic deterioration.
    Type: Grant
    Filed: October 26, 2023
    Date of Patent: July 30, 2024
    Assignee: Prothena Biosciences Limited
    Inventors: Andriani Ioannou, Tarlochan S. Nijjar, Philip James Dolan, III, Wagner Zago
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20240209073
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: January 25, 2024
    Publication date: June 27, 2024
    Applicant: Prothena Biosciences Limited
    Inventors: Tarlochan S. Nijjar, Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Antibodies recognizing tau
    Patent number: 11958896
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: April 16, 2024
    Assignee: Prothena Biosciences Limited
    Inventors: Robin Barbour, Svetlana Alexander, Mark Renz, Shuning Gai, Tarlochan S. Nijjar, Philip James Dolan, III, Philip Payne
  • Antibodies recognizing tau
    Patent number: 11926659
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: March 12, 2024
    Assignee: Prothena Biosciences Limited
    Inventors: Tarlochan S. Nijjar, Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • METHODS OF USING ANTIBODIES RECOGNIZING TAU
    Publication number: 20240018226
    Abstract: The invention provides methods of treating taupathies such as Alzheimer's disease with antibodies that bind to human tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: August 28, 2023
    Publication date: January 18, 2024
    Applicant: Prothena Biosciences Limited
    Inventor: Philip James Dolan, III
  • Tau Immunotherapy
    Publication number: 20230340094
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: April 21, 2023
    Publication date: October 26, 2023
    Applicant: Prothena Biosciences Limited
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • METHODS OF TREATING AL AMYLOIDOSIS
    Publication number: 20230331831
    Abstract: Antibody formulations and methods useful for treatment of patients with AL amyloidosis.
    Type: Application
    Filed: May 8, 2023
    Publication date: October 19, 2023
    Applicant: Prothena Biosciences Limited
    Inventors: Gene Kinney, Wagner Marcelo Zago, Carol Karp, Radhika Tripuraneni
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20230250161
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: February 17, 2023
    Publication date: August 10, 2023
    Applicant: Prothena Biosciences Limited
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Methods of treating AL amyloidosis
    Patent number: 11692024
    Abstract: Antibody formulations and methods useful for treatment of patients with AL amyloidosis.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: July 4, 2023
    Assignee: Prothena Biosciences Limited
    Inventors: Gene Kinney, Carol Karp, Wagner Marcelo Zago, Radhika Tripuraneni
  • Tau immunotherapy
    Patent number: 11643457
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: May 9, 2023
    Assignee: Prothena Biosciences Limited
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Antibodies recognizing tau
    Patent number: 11584791
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: February 21, 2023
    Assignee: Prothena Biosciences Limited
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20220372118
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: November 4, 2020
    Publication date: November 24, 2022
    Applicant: Prothena Biosciences Limited
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20220275067
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: February 7, 2020
    Publication date: September 1, 2022
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Philip James DOLAN, III, Tarlochan S. NIJJAR, Svetlana ALEXANDER, Robin BARBOUR, Stephen Jed TAM
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 11345749
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: May 31, 2022
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose William Saldanha, Tarlochan S. Nijjar
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20220089702
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: May 2, 2018
    Publication date: March 24, 2022
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin BARBOUR, Svetlana ALEXANDER, Mark RENZ, Shuning GAI, Tarlochan S. NIJJAR, Philip James DOLAN, III, Philip PAYNE